PKM and glioblastoma: To define the clinical relevance of our finding that Cdc25A regulates PKM2- and β-catenin-dependent gene expression, we performed immunohistochemistry (IHC) analyses of 88 human primary GBM specimens (World Health Organization (WHO) grade IV) with antibodies against Cdc25A pY59, PKM2 and Cdc25A.